Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Deep vein thrombosis cost-effectiveness of therapy
Introduction
Editor(s)-In-Chief: The APEX Trial Investigators, C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [2] Ujjwal Rastogi, MBBS [3]; Kashish Goel, M.D.; Assistant Editor(s)-In-Chief: Justine Cadet
Overview
Overview
In the United States, deep vein thrombosis DVT and pulmonary embolism PE costs are more than $9,800 and $14,000 for initial hospitalization respectively, and more than $11,800 and $14,700 for rehospitalization (over half of which occurs within 90 days), respectively.[1] Several studies have reported that prophylaxis therapy against VTE among surgical patients is cost effective.[2] According to the Canadian cost-effectiveness guidelines in the early 1990s, there is moderate to strong evidence to adopt enoxaparin prophylaxis against DVT after total hip replacement.[3]
References
References
- ↑ Spyropoulos AC, Lin J (2007). “Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations”. J Manag Care Pharm. 13 (6): 475–86. PMID 17672809.
- ↑ Anderson DR, O’Brien BJ (1997). “Cost effectiveness of the prevention and treatment of deep vein thrombosis and pulmonary embolism”. Pharmacoeconomics. 12 (1): 17–29. PMID 10169385.
- ↑ O’Brien BJ, Anderson DR, Goeree R (1994). “Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement”. CMAJ. 150 (7): 1083–90. PMC 1486381. PMID 8137188. Unknown parameter
|month=ignored (help)